{
    "nctId": "NCT01216111",
    "briefTitle": "Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)",
    "officialTitle": "A Prospective\uff0c Randomized\uff0c Open-label\uff0c Multicentric\uff0cphaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 647,
    "primaryOutcomeMeasure": "disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women aged from 18 to 70 years;\n2. Histologically proven invasive unilateral breast cancer (regardless of the type);\n3. Initial clinical condition compatible with complete initial resection;\n4. No residual macro or microscopic tumor after surgical excision;\n5. Beginning of chemotherapeutic treatment no later than day 42 after the initial surgery;\n6. positive lymph node or negative lymph node with tumor size \\> 1.0cm\n7. Patient presenting one of the following criteria (reviewed before randomization by referent pathologist):\n\n   Triple negative \uff08ER-PR-Her-2-\uff09 Hormone receptor negativity is defined as ER\\<1%, PR\\<1% (IHC), HER2 negativity is defined as IHC 0-1+, or \\[IHC 2+ and FISH or CISH negative\\].\n8. No clinically or radiologically detectable metastases (M0);\n9. No peripheral neuropathy \\> 1;\n10. WHO Performance status (ECOG) of 0 or 1;\n11. Adequate recovery from recent surgery (at least one week must have elapsed from the time of a minor surgery (excluding breast biopsy); at least three weeks for major surgery);\n12. Adequate hematological function (neutrophil count \u00b3 2x109/l, platelet count \u00b3 100x 109/l, Hemoglobin \\> 9 g/dl);\n13. Adequate hepatic function: ASAT and ALAT \u2264 3 ULN alkaline phosphatases \u2264 2.5 ULN,total bilirubin \u2264 1,5 ULN;\n14. Adequate renal function: serum creatinine \u2264 1 ULN;\n15. Patients accepting contraception intake during the overall length of treatment if of childbearing potential;\n16. Adequate cardiac function, LEVF value \\> 50% by Muga scan or echocardiography;\n17. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Bilateral breast cancer or patient with controlateral DCIS;\n2. Any metastatic impairment, including homolateral sub-clavicular node involvement,regardless of its type;\n3. Any T4 lesion (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);\n4. ER+ or PR+ or Her-2 overexpression\n5. Any clinically or radiologically suspect and non-explored damage to the controlateral breast;\n6. Any chemotherapy, hormonal therapy or radiotherapy before surgery;\n7. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheral ephitelioma) in the preceding 5 years, including invasive controlateral breast cancer;\n8. Patients already included in another therapeutic trial involving an experimental drug;\n9. Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study;\n10. LEVF \\< 50% (MUGA scan or echocardiography);\n11. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (\\>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to randomization;\n12. Known prior severe hypersensitivity reactions to agents containing Cremophor EL;\n13. Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 8 weeks after treatment completion;\n14. Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase;\n15. Women with a positive pregnancy test en enrollment or prior to study drug administration;\n16. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;\n17. Individual deprived of liberty or placed under the authority of a tutor.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}